NIH Clinical Research Studies Listed By Institute of the Principal Investigator

National Institute of Allergy and Infectious Diseases (NIAID)

139 Protocols (106 Active Accrual of new subjects, 33 Follow-up of previously enrolled subjects)

Active Accrual, Protocols Recruiting New Patients 
* 08-I-0209:
A Multicenter, Randomized Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Tolerability, and Efficacy of AVONEX in Subjects with Moderate to Severe Ulcerative Colitis

* 08-I-0201:
Pioglitazone for Hepatic Steatosis in HIV/HCV Co-infection

* 08-I-0184:
Studies in the Pathogenesis of Idiopathic Anaphylaxis

* 08-I-0174:
A Pilot Study of Therapy with Pioglitazone Prior to HCV Treatment in HIV-1 and HCV Genotype 1-Infected Subjects with Insulin Resistance Who Are Prior Nonresponders to Peginterferon and Ribavirin Therapy

* 08-I-0171:
A Phase I, Open Label, CT to Evaluate the Safety, Tolerability and Immunogenicity of a Multiclade Recombinant HIV-1 Adenoviral Vector Vaccine, VRC-HIVADV014-00-VP In Uninfected Adults Randomized to Needle or Biojector Methods of Intramuscular Injection

* 08-I-0093:
A Phase I Double-Blind, Placebo-Controlled, Dose-Escalating Study to Evaluate the Safety and Tolerability of Topical Nasal Poly-ICLC

* 08-I-0065:
VRC 206: A Phase I Study to Evaluate the Safety and Immunogenicity of an Ebola DNA Plasmid Vaccine, VRC-EBODNA023-00-VP, and a Marburg DNA Plasmid Vaccine, VRC-MARDNA025-00-VP, in Healthy Adults

* 08-I-0063:
A Phase III, Multicenter Placebo-Controlled, Randomized, Double-Blind Study to Evaluate Safety/Efficacy of PROCHYMALTM IV Infusion for Induction of Remission in Subjects Experiencing Tx of Refractory Moderate to Severe Crohn's Disease

* 08-I-0053:
Pilot (Phase I-II) Study of Valproic Acid (Depakote) for the Treatment of the Autoimmune Lymphoproliferative Syndrome (ALPS)

* 08-I-0034:
Validation of (1)H-Magnetic Resonance Spectroscopy for Quantification of Hepatic Triglyceride Content

* 07-I-0229:
Influenza in the Immunocompromised Host

* 07-I-0218:
A Double-Blind, Randomized, Placebo-Controlled Cross-Over Study Assessing the Role of Pathogen-Specific IgE and Histamine Release in the Hyper-IgE Syndrome and the Effect of Ranitidine on Laboratory and Clinical Manifestations

* 07-I-0205:
An Observational Study of the Immunopathogenesis of and Response to Step-Up Inflammatory Bowel Disease Therapy for Hermansky-Pudlak Syndrome-Associated Colitis

* 07-I-0183:
The Collection of Research Samples and/or Data for Repository from Related or Unrelated Hematopoietic Stem Cell Transplantation Recipients for the National Marrow Donor Program

* 07-I-0171:
Treatment for Growth Failure in Patients with X-Linked Severe Combined Immunodeficiency (XSCID): A Phase 2 Study Assessing Safety and Clinical Response to Treatment with Insulin-like Growth Factor-1 (IGF-1)

* 07-I-0167:
VRC 012: A Phase I Clinical Trial of the Safety and Immunogenicity of an HIV-1 Adenoviral Vector Serotype 35 Vaccine: Dose Escalation as a Single Agent and Prime-Boost Schedules with an HIV-1 Adenoviral Vector Serotype 5 Vaccine in Uninfected Adults

* 07-I-0142:
Research Respiratory Tract Procedures in Healthy Adult Volunteers and Adult Patients to Obtain Specimens for In Vitro Analyses of Infection Pathogenesis and Susceptibility

* 07-I-0105:
Pioglitazone for Hepatic Steatosis in HIV

* 07-I-0094:
Accuracy of Hemoglobin A1C to Predict Glycemia in HIV

* 07-I-0075:
Allogeneic and Matched Unrelated Donor Stem Cell Transplantation for Congenital Immunodeficiencies: Busulfan-based Conditioning with Campath- 1H or h-ATG, Radiation, and Sirolimus

* 07-I-0033:
Screening Protocol for Detection and Characterization of Infections and Infection Susceptibility

* 07-I-0017:
Autologous Transplantation of Genetically Modified Cells for the Treatment of X-Linked Chronic Granulomatous Disease

* 07-I-0001:
An Open Label Non-Randomized Trial to Assess Safety and Tolerability of Alb-Interferon Alfa 2b Every Two Weeks with Ribavirin among HIV/HCV Coinfected Individuals

* 06-I-0237:
A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of a Recombinant Ebola Adenoviral Vector Vaccine, VRC-EBOADV018-00-VP, in Healthy Adults

* 06-I-0235:
A Phase II Vaccine Dose Finding Pilot Study for Development of an Anti-Influenza A (H5N1) Intravenous Hyper-Immune Globulin

* 06-I-0217:
Genetic Disorders of Mucociliary Clearance

* 06-I-0207:
Investigation of Southern Tick-Associated Rash Illness (STARI)

* 06-I-0197:
A Randomized Placebo Controlled Trial of Atorvastatin in HIV Positive Patients Not on Antiretroviral Medications with the Specific Aims of Studying the Effects of Atorvastatin on HIV Viral Load and Immune Activation Markers

* 06-I-0160:
Infliximab Treatment for Crohn's-like Inflammatory Bowel Disease in Chronic Granulomatous Disease: A Phase I/II Study Assessing Clinical and Immune Responses to Treatment and Genetic Influences

* 06-I-0106:
High Dose Versus Standard-Dose Oseltamivir for the Treatment of Severe Influenza and Avian Influenza: A Phase II Double-Blind, Randomized Clinical Trial

* 06-I-0086:
A Cohort Observational Study Evaluating Predictors, Incidence and Immunopathogenesis of Immune Reconstitution Syndrome (IRIS) in HIV-1 Infected Patients with CD4 Count Less Than or Equal to 100 Cells/micro L Who Are Initiating Antiretroviral Therapy

* 06-I-0077:
Voriconazole Plasma Concentration and Toxicity

* 06-I-0074:
Collection of Blood from Persons with Hemoglobin and Erythrocyte Polymorphisms for Laboratory Malaria Research

* 06-I-0049:
Studies of Disorders in Antibody Production and Related Primary Immunodeficiency States

* 06-I-0032:
Pilot Study of Omalizumab (Xolair) in Hyper IgE (Job's) Syndrome

* 06-I-0030:
Correlation of the Precursor Frequency of CD4 + Effector Memory T Cells with Induration Measured in the Tuberculin Skin Test (TST)

* 06-I-0015:
Screening Protocol for Genetic Diseases of Lymphocyte Homeostasis and Programmed Cell Death

* 06-I-0005:
Evaluation of Risk Factors for Development of Epstein-Barr Virus Lymphoproliferative Disease

* 05-I-0219:
Microarray Analysis of Erythema Migrans Lesions

* 05-I-0213:
Screening and Baseline Assessment of Patients with Abnormalities of Immune Function

* 05-I-0156:
A Study of Adjuvant Cytokine Therapy in Pulmonary Mycobacterium Avium Complex Infection

* 05-I-0123:
A Randomized, Open-Label, International Study of Subcutaneous Recombinant Interleukin-2 (rIL-2, Aldesleukin) with and without Concomitant Antiretroviral Therapy in Participants w/HIV-1 Infection and CD4+ Cell Counts Greater Than or Equal to 300/mm(3)

* 05-I-0084:
Clinical and Immunological Evaluation of Children with Allergic Disease

* 04-I-0286:
A Longitudinal Study of Familial Hypereosinophilia (FE): Natural History and Markers of Disease Progression

* 04-I-0231:
Procurement of Clinical Specimens for Immunologic or Genetic Studies in Inflammatory Bowel Diseases

* 04-I-0086:
Leukapheresis Procedures to Obtain Plasma and Lymphocytes for Research on HCV-Infected Patients

* 04-I-0030:
Clinical Evaluation and Management of Persons with Severe Acute Respiratory Syndrome (SARS)

* 03-I-0285:
VRC 300: Screening of Healthy Volunteers for Clinical Trials of Investigational Vaccines to Prevent Infectious Diseases

* 03-I-0263:
Apheresis and Specimen Collection Procedures to Obtain Plasma, Peripheral Blood Mononuclear Cells (PBMCs) and Other Specimens for Research Studies

* 03-I-0151:
Evaluation and Treatment of Persons with Serious Complications Associated with Vaccinia Vaccination

* 03-I-0090:
Immune Responses to Vaccinia Virus Vaccination

* 03-I-0079:
Screening HIV-Infected Subjects for Vaccine Research Studies

* 03-I-0041:
Determining the Pathogenesis of Systemic Pediatric-Onset Mastocytosis

* 03-I-0025:
Treatment of Chronic Graft Versus Host Disease with Extracorporeal Photopheresis

* 02-I-0308:
Study of Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) for the Evaluation of the Autoimmune Lymphoproliferative Syndrome (ALPS) and ALPS-Associated Lymphoma

* 02-I-0286:
A Pilot Study of the Safety and Efficacy of Imatinib Mesylate in Reducing Eosinophilia in Patients with the Myeloproliferative Variant Hypereosinophilic Syndrome (HES) or Non-Myeloproliferative HES Refractory to Standard Therapy

* 02-I-0277:
Regulation of the Proliferation and Survival of Normal and Neoplastic Human Mast Cells

* 02-I-0232:
HIV Expression in Patients with Viral Loads Suppressed on HAART

* 02-I-0202:
Leukapheresis Procedures to Obtain Plasma and Lymphocytes for Research Studies on Antiretroviral Naive HIV-Infected Patients

* 02-I-0147:
Genetic Studies of Chronic Active Epstein-Barr Virus Infection

* 02-I-0127:
Screening Subjects for HIV Vaccine Research Studies

* 02-I-0110:
Natural History of Anthrax: A Study of Primary Infected, Recovered, and Exposed (SPoRE) Individuals and Evaluation of AVA Vaccinated Recipients

* 02-I-0096:
Rituximab (Anti-CD20) for the Treatment of Hepatitis C Associated Cryoglobulinemic Vasculitis

* 02-I-0086:
Leukapheresis Procedures to Study HIV-Specific Immunity

* 02-I-0057:
Ex Vivo Retroviral Gene Transfer For Treatment of X-Linked Severe Combined Immunodeficiency (XSCID)

* 02-I-0055:
Evaluation, Treatment and Follow up of Patients with Lyme Disease

* 01-I-0238:
Diagnosis and Treatment of Leishmanial Infections

* 01-I-0226:
Evaluation of Immune Response to Vaccines in Primary Immune Disorders

* 01-I-0225:
An Omnibus Proleukin (IL-2) Trial in HIV-Infected Patients Including Interrupted Versus Continuous Antiretrovirals (OPTICA): A Substudy of Interrupted Versus Continuous Antiretrovirals Involving Randomization From the Umbrella Study (ICARUS)

* 01-I-0202:
Natural History, Genetics, Phenotype and Treatment of Mycobacterial Infections

* 01-I-0194:
A Non-Randomized, Open label, Study to Assess Hepatitis C Viral Kinetics in Predicting the Clinical Response in Patients with Hepatitis C Infection Coinfected with HIV-1 Treated with Peginterferon Alpha-2b and Ribavirin

* 01-I-0161:
Identification of Novel Viruses

* 01-I-0153:
The Immune Basis for the Gastrointestinal Complications of Common Variable Immunodeficiency

* 01-I-0004:
An Assessment of the Relationship Between Antiretroviral Drug Genotype/Phenotype (IC50) and Antiretroviral Activity in HIV-Infected, Drug-Experienced Patients with Suboptimal Suppression of Plasma Viral Load

* 00-I-0159:
Natural History, Management, and Genetics of the Hyperimmunoglobulin E Recurrent Infection (Job) Syndrome

* 00-I-0099:
Langherhans' Cell Function and Inflammatory Responses in Skin of Normal Volunteers and Patients with Helminth Infections Using the Suction Blister Technique

* 99-I-0084:
To Develop a New Technique to Predict the Occurrence of Pneumocystis Pneumonia, Track its Epidemiology, Diagnose Acute Disease, and Predict and Monitor the Response to Various Therapeutic Agents

* 98-I-0070:
Magnetic Resonance Imaging to Study Avascular Necrosis in HIV-Infected Subjects

* 98-I-0027:
The Characterization of CD34+ Derived Mast Cell Precursors Mobilized by Administration of Granulocyte Colony Stimulating Factor

* 97-I-0191:
Studies of Lymphocyte Kinetics Using Stable Isotopes

* 97-I-0096:
Evaluation, Treatment, and Monitoring of Patients With Known or Suspected Parasitic Infection

* 96-I-0129:
Evaluation and Long Term Follow-up of Patients with Allergic and Inflammatory Disorders

* 96-I-0085:
Genetic Studies of the X-Linked Lymphoproliferative Disease

* 96-I-0052:
A Comprehensive Clinical, Microbiological and Immunological Assessment of Patients with Suspected Chronic Lyme Infection and Selected Control Populations

* 95-I-0072:
Clinical, Virologic, and Immunologic Evaluation and Monitoring of Patients with Known or Suspected HIV Infection

* 95-I-0066:
Genetic Analysis of Immune Disorders

* 95-I-0027:
Virologic and Immunologic Evaluation of Lymph Node, Tonsillar, and Intestinal Biopsies, and Bronchoalveolar Lavage Fluid

* 94-I-0079:
Eosinophil Activation and Function in Parasitic Infections and Other Conditions with Increased Tissue or Peripheral Blood Eosinophilia in Humans

* 94-I-0073:
Recruitment of Peripheral Blood Hematopoietic Progenitors by Granulocyte Colony Stimulating Factor (G-CSF)

* 93-I-0119:
Detection and Characterization of Host Defense Defects

* 93-I-0106:
Cryptococcosis in Previously Normal Adults

* 93-I-0086:
Evaluation and Long Term Follow Up of Patients with Acute or Chronic Inflammatory Disorders

* 93-I-0063:
Study of the Immunopathogenesis, Natural History, and Genetics of Autoimmune Lymphoproliferative Syndrome (ALPS) Associated with an Expansion of CD4-8-/TCR alpha/beta+ T Cells and Defective Lymphocyte Apoptosis

* 93-I-0057:
Apheresis Procedures to Obtain Plasma or Leukocytes for In Vitro Studies

* 92-I-0125:
A Study of Viral Burden in Peripheral Blood versus Lymphoid and Bone Marrow Tissue in Human Immunodeficiency Virus Infected Individuals

* 91-I-0140:
Studies of the Pathogenesis of HIV Infection in Human Peripheral Blood Cells and/or Reproductive Fluids in HIV-Infected and HIV-Uninfected Volunteers

* 90-I-0120:
Comparison of Inflammatory Responses in Normal Volunteers and Patients with Abnormal Phagocyte Function Using the Suction Blister Technique

* 89-I-0174:
Study of Patients with Known or Suspected Infection with Strongyloides Stercoralis

* 89-I-0158:
Studies of Immune Regulation in Patients with Common Variable Immunodeficiency and Related Humoral Immunodeficiency Syndromes

* 88-I-0083:
Host Response to Infection and Treatment in the Filarial Diseases of Humans

Next 39 Protocols

Command Menu Bar

Search The Studies | Help | Questions |
Clinical Center Home | NIH Home

Clinical Center LogoNational Institutes of Health Clinical Center
Bethesda, Maryland 20892. Last update: 09/17/2008

Search The Studies Help Questions
Search The Studies Help Questions